Aardvark Therapeutics Unblinds Trial Data After FDA Clinical Hold on ARD-101

Event summary

  • FDA placed a full clinical hold on Aardvark Therapeutics' ARD-101 IND, halting Phase 3 HERO and OLE trials for Prader-Willi Syndrome (PWS).
  • Aardvark plans to unblind data from 68 patients in HERO trial and 19 in OLE trial to assess efficacy and safety.
  • Company has $91.2 million in cash, sufficient to fund operations into mid-2027.
  • ARD-101 is an oral small-molecule therapeutic targeting hyperphagia in PWS via bitter taste receptor activation.

The big picture

The FDA clinical hold on ARD-101 highlights the regulatory risks in rare disease drug development, particularly for novel mechanisms like bitter taste receptor activation. Aardvark's ability to pivot from trial pauses to data-driven decision-making will test its operational resilience in a competitive metabolic disease space. The company's cash position provides a 12-month buffer, but market confidence hinges on resolving the hold without major trial redesigns.

What we're watching

Regulatory Resolution
How quickly Aardvark can negotiate FDA's clinical hold and resume trials will determine ARD-101's near-term viability.
Data Interpretation
Whether unblinded trial data reveals sufficient efficacy/safety signals to justify continued development despite the hold.
Financial Runway
The pace at which Aardvark burns through its $91.2 million cash reserve while navigating regulatory challenges.